Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
Key facts
- Where
- Beijing, Chongqing, Guangzhou, Haikou, Jining, Shanghai, and Zhengzhou, ChinaSee the 11 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07141251, who can take part
Where in China
- Beijing Anzhen Hospital, Capital Medical UniversityBeijing, ChinaContact: Bao LiuTaking people
- Fuwai Hospital ，CAMS&PUMCBeijing, ChinaContact: Bao LiuTaking people
- Peking Union Medical College HospitalBeijing, ChinaContact: Bao LiuTaking people
- The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaContact: Bao LiuTaking people
- The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Bao LiuTaking people
- Hainan General HospitalHaikou, ChinaContact: Bao LiuTaking people
- The Affiliated Hospital of Jining Medical UniversityJining, ChinaContact: Bao LiuTaking people
- Changhai HospitalShanghai, ChinaContact: Bao LiuTaking people
- Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Bao LiuTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Bao LiuTaking people
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaContact: Bao LiuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07141251
- Record updated
- 15 October 2026
- Original description
Multi-Branch AOrtic Reconstruction With G-iliac System (BAO-G) Technique is a novel technique of endovascular repair of complex aortic aneurysm, which using off-the-shelf iliac branched devices to reconstruct the visceral branches. This study aims to verify the perioperative safety and 5-year efficacy of BAO-G technique in the endovascular treatment of complex aortic aneurysms through a prospective, multicenter, open-label, single-arm clinical trial, and to provide evidence for the selection of clinical procedures for complex aortic aneurysm patients in the future.Read full original descriptionShow less
Multicenter, Open-labeled, Single-arm Clinical Trial of Multi-Branch AOrtic Reconstruction of Complex Aortic Aneurysm With G-iliac System [BAO-G] Technique
Multi-Branch AOrtic Reconstruction With G-iliac System (BAO-G) Technique is a novel technique of endovascular repair of complex aortic aneurysm, which using off-the-shelf iliac branched devices to reconstruct the visceral branches. This study aims to verify the perioperative safety and 5-year efficacy of BAO-G technique in the endovascular treatment of complex aortic aneurysms through a prospective, multicenter, open-label, single-arm clinical trial, and to provide evidence for the selection of clinical procedures for complex aortic aneurysm patients in the future.
Inclusion: Diagnosed with Crawford type Ⅰ- Ⅴ thoracoabdominal aortic aneurysm or complex abdominal aortic aneurysm, with a healthy proximal landing zone (>20mm length, angulation <60°) in the descending aorta and maximum aneurysm diameter ≥4cm; Patients with pseudoaneurysms, post-dissection aneurysmal degeneration, or failure of previous EVAR were also eligible if the pathology involved the visceral aortic segment; Scheduled for endovascular aortic repair with commercially available iliac branch devices for visceral artery reconstruction; Signed informed consent and committed to protocol-defined follow-up.
Exclusion: Concurrent participation in other interventional clinical trials; Acquired language barrier, intellectual decline, cognitive impairment, or mental illness preventing informed consent; Uncontrolled autoimmune diseases (e.g., Takayasu arteritis, systemic lupus erythematosus, vasculitis); End-stage renal/hepatic/cardiac/pulmonary failure or malignancy diagnosed within 5 years, likely to cause mortality during follow-up; Active bleeding or coagulopathy within 6 months (high bleeding risk); Uncontrolled hypertension (resting SBP >180 mmHg or DBP >110 mmHg); Uncontrolled diabetes (fasting blood glucose >16.7 mmol/L); Severe hepatic/renal dysfunction (serum creatinine >3 mg/dL, ALT/AST >3×ULN); Pregnancy or perinatal status; Refusal to sign informed consent.